NAD+ drips have become the visible face of the longevity-clinic economy — a bag of clear fluid, an hour in a recliner, a price tag in the hundreds. The pitch is simple: your NAD+ falls as you age, so put it back. In 2026 that pitch has been squeezed from two directions at once. A large multi-cohort study in Nature Metabolism reported that whole-blood NAD+ doesn't actually vary with age, and a September 2026 review of intravenous NAD+ concluded the clinical evidence is still "preliminary and insufficient" for routine use. This post walks through what the NAD+ research now shows about the IV route specifically, and where NAD+ Australia sits under the TGA — including the question readers ask most: is NAD+ legal in Australia?

If you want the broader background on the molecule, start with our NAD+ compound profile.

What Is NAD+, and Why Does the Drip Exist?

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme, not a peptide. It sits at the centre of energy metabolism and is consumed by enzymes involved in DNA repair and cellular signalling, including sirtuins and PARPs. Because the molecule is large and charged, oral NAD+ is poorly absorbed intact — which is the core marketing argument for infusing it directly.

Precursors take a different route. Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are smaller salvage-pathway intermediates the body converts into NAD+. Most of the human trial literature is on those oral precursors, not on IV NAD+ itself. We've covered how the oral NMN and NR trials stack up against each other separately; this piece is about what happens when the coenzyme goes into a vein.

The Premise Took a Hit in 2026

The foundational claim behind NAD+ therapy is that levels decline with age. A 2026 Nature Metabolism paper by Trętowicz and colleagues tested that directly, quantifying NAD+ across seven independent human cohorts using validated mass spectrometry. Whole-blood NAD+ levels did not vary meaningfully with age, and did not shift with lifestyle interventions including exercise and nutritional support in frail older adults. Notably, they did rise with nicotinamide riboside supplementation — so the assay works; it simply didn't find the age effect the field assumed.

Two honest caveats. First, this is blood, not tissue: intracellular NAD+ in muscle, liver or brain may behave differently, and the paper doesn't rule that out. Second, the same journal's accompanying commentary framed the result as a reason to rethink blood NAD+ as a biomarker of healthy ageing, not as proof that NAD+ biology is irrelevant to disease. But it does undercut the specific pitch that a blood test showing "low NAD+" justifies an infusion.

What the IV Head-to-Head Data Actually Show

There is now a small amount of direct comparison data, and it is worth reading with the funding disclosures open.

The acute randomised pilot

A randomised, double-blind, placebo-controlled pilot posted to medRxiv in 2024 compared a single 500 mg NR IV, 500 mg NAD+ IV, oral NR and saline placebo in healthy adults (37 participants in phase one, 16 in phase two). NR IV raised blood NAD+ by about 20.7% above baseline at peak and significantly outperformed both NAD+ IV and oral NR at three hours. NR IV also infused faster and was better tolerated; NAD+ IV was associated with increases in white cell and neutrophil counts, which the authors flagged as a possible inflammatory response.

The disclosure matters: the study was funded by ChromaDex, which sells the NR product tested, and several authors are ChromaDex employees. It is a preprint-stage pilot with a commercial interest in one arm — hypothesis-generating, not settled.

The real-world retrospective

A retrospective tolerability study published in Frontiers in Aging in February 2026 (Reyna et al., with the paper indexed among Edith Cowan University's research outputs) reviewed electronic medical records from a commercial clinic where people received four consecutive days of 500 mg NAD+ IV or NR IV, with 30-day follow-up. Both were tolerated without clinically significant changes in liver enzymes or inflammatory markers. But it was a chart review, not a randomised trial, the exploratory metabolic outcomes were variable, and nothing beyond 30 days was assessed.

The review's verdict

The September 2026 narrative review in the same journal pulled the field together and was blunt: mechanistic rationale exists, but efficacy, durability, optimal dosing and long-term safety cannot currently be established. Reported infusion-related effects include nausea, cramping, flushing and chest discomfort — generally linked to infusing too quickly. Larger randomised trials with standardised protocols and clinically meaningful endpoints are needed before IV NAD+ counts as evidence-based practice.

Put plainly: no adequately powered randomised trial has shown that an NAD+ drip improves a clinical outcome that patients care about, and no trial has shown IV beats oral for anything other than short-term blood levels.

NAD+ Australia: Is NAD+ Legal in Australia?

This is where the Australian picture is unusually clear-cut, and it doesn't match the marketing.

  • NAD+ and NADH are not permitted ingredients for listed medicines in Australia. The TGA has published a safety alert about NAD, NAD+, NADH and NMN medicines sold in Australia, reiterating that anything supplied as a medicine must be on the ARTG unless exempt or otherwise authorised.
  • Nicotinamide riboside (NR) is a permitted ingredient, so compliant NR listed supplements can be sold here.
  • Oral NMN was permitted from 10 December 2025, capped at 500 mg per day for up to 12 weeks of use, under an arrangement exclusive to the sponsoring company until December 2027. The FDA separately reversed its NMN exclusion in September 2025.
  • Injectable and IV forms are a different category again. They are not ARTG-registered consumer products; where they appear in clinics, they generally arrive via compounding or personal-importation pathways, and TGA guidance treats IV therapies as higher-risk compounded products with extra requirements.

There is also an advertising dimension. Back in November 2022, AHPRA and the National Boards wrote to businesses warning that IV infusion advertising may breach the National Law, noting the marketing of immunity and anti-ageing claims has outpaced the evidence. Nothing published since has changed that assessment for NAD+ — if anything, the 2026 literature strengthens it.

So: legal status depends entirely on the form. An oral NR supplement on the ARTG is a regulated listed medicine. An NAD+ drip is an unapproved therapy delivered under a practitioner's clinical discretion, not a product the TGA has evaluated for this use.

How to Read the Next Wave of NAD+ Research

Three filters will save you time:

  1. Check what was measured. "Raises blood NAD+" is a pharmacokinetic result, not a health outcome. The 2026 Nature Metabolism data suggest blood NAD+ may not even be the right yardstick.
  2. Check who paid. The most-quoted IV head-to-head was funded by a company selling one of the arms. That doesn't make it wrong; it makes replication essential.
  3. Check the design. Retrospective chart reviews and open-label pilots describe tolerability well and prove efficacy poorly.

For profiles of other compounds in this space and how we grade their evidence, see the peptides index. If you'd like new NAD+ and peptide research summarised as it lands — including any change to the TGA's position — join the free updates list.

FAQ

Does NAD+ really decline with age?

A 2026 Nature Metabolism study across seven human cohorts found whole-blood NAD+ did not vary with age or with lifestyle interventions, though it did rise with NR supplementation. That challenges the standard "top up your falling NAD+" premise, at least for blood; tissue-level NAD+ may behave differently and remains under study.

Is NAD+ IV therapy legal in Australia?

NAD+ and NADH are not permitted ingredients for listed medicines in Australia, and no NAD+ infusion product is ARTG-registered for anti-ageing use. IV NAD+ in clinics sits in the unapproved/compounded space, and AHPRA has previously warned businesses about advertising unproven IV infusion treatments.

Is an NAD+ drip better than oral NMN or NR?

There is no adequately powered trial showing IV beats oral on any clinical outcome. One company-funded randomised pilot found NR IV raised blood NAD+ faster than NAD+ IV or oral NR at three hours, but that is a short-term biomarker result from a preprint with clear commercial involvement.

Is NAD+ a peptide?

No. NAD+ is a coenzyme (a dinucleotide), not a peptide. It's covered on this site because it shares the same longevity-clinic and research-compound ecosystem as the peptides we profile.

Sources

This article is information only, not medical advice. retatrutide.net.au is independent and does not sell or supply any product. NAD+ and NADH are not permitted ingredients in Australian listed medicines and no NAD+ infusion is TGA-approved for anti-ageing use; oral NR is permitted and oral NMN has been permitted since 10 December 2025 under specific limits.